Suboxone Does NOT Contain Naltrexone and Should NOT Cause False-Positive Oxycodone Screens
Suboxone contains naloxone (not naltrexone), and while it should not directly cause a false-positive urine drug screen for oxycodone, you need to be aware that standard opiate immunoassays may not detect buprenorphine at all, and cross-reactivity issues exist with certain testing platforms.
Critical Clarification on Suboxone Components
First, let's correct a fundamental misconception: Suboxone contains buprenorphine plus naloxone, NOT naltrexone 1. These are completely different medications:
- Naloxone: Short-acting opioid antagonist in Suboxone (4:1 ratio with buprenorphine), included to deter IV misuse
- Naltrexone: Separate opioid antagonist medication used for alcohol/opioid dependence treatment
Interestingly, naltrexone itself can cause false-positive oxycodone screens through its metabolite noroxymorphone 2, but this is irrelevant to Suboxone.
Buprenorphine Detection Issues
Standard Opiate Panels Miss Buprenorphine
Standard urine opiate immunoassays detect morphine and codeine but NOT synthetic opioids like buprenorphine, oxycodone, or hydrocodone 3, 4. This means:
- Patients on Suboxone will typically test negative on standard opiate screens
- You need a specific buprenorphine immunoassay to detect buprenorphine use
- The buprenorphine assay uses a 5 ng/mL cutoff and has 100% sensitivity when confirmed by LC-MS-MS 5
False-Positive Considerations
While buprenorphine itself should not cross-react with oxycodone assays, be aware of these testing pitfalls:
Opiate interference with buprenorphine assays: High opiate concentrations (≥2000 µg/L) can cause false-positive buprenorphine screens 6. This is the reverse of your question but highlights cross-reactivity issues.
Common medications causing false-positive opioid screens include fluoroquinolone antibiotics, which can cross-react with opiate immunoassays 4, 7. However, these don't specifically relate to Suboxone use.
Clinical Approach to Discordant Results
When you encounter a positive oxycodone screen in a patient prescribed Suboxone:
- Assume non-prescribed opioid use first - Buprenorphine does not metabolize to oxycodone
- Order confirmatory testing - Use LC-MS-MS or GC-MS to definitively identify the substance 4, 7
- Review complete medication list - Check for other medications that might cause cross-reactivity
- Check prescription drug monitoring program - Verify no concurrent oxycodone prescriptions
- Consider specimen validity - Temperature (90-100°F within 4 minutes), creatinine (>20 mg/dL), and adulterants 4, 5
Important Testing Caveats
False-negative buprenorphine results occur in 15-16% of compliant patients, particularly with low-dose patches 5, 8. In one study, 33 of 216 samples (15.3%) from patients on Suboxone had no detectable buprenorphine 5.
Immunoassay limitations: The false-positive rate for opiates (excluding oxycodone) can be as high as 34%, and confirmatory testing is essential 9.
Bottom Line
If a patient on Suboxone tests positive for oxycodone, this represents either true oxycodone use or a false-positive requiring confirmatory testing 4, 7. Suboxone (buprenorphine/naloxone) does not metabolize to oxycodone and should not cause this result. Always confirm positive immunoassay screens with chromatography-mass spectrometry before making clinical decisions that could damage the therapeutic relationship or result in treatment discontinuation 4.